The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease

BACKGROUND: Intrahepatic cholangiocarcinoma (iCCA) is a highly aggressive primary liver tumor with increasing incidence worldwide, dismal prognosis, and few therapeutic options. Mounting evidence underlines the role of the Hippo pathway in this disease; however, the molecular mechanisms whereby the...

Descripción completa

Detalles Bibliográficos
Autores principales: Cigliano, Antonio, Zhang, Shanshan, Ribback, Silvia, Steinmann, Sara, Sini, Marcella, Ament, Cindy E., Utpatel, Kirsten, Song, Xinhua, Wang, Jingxiao, Pilo, Maria G., Berger, Fabian, Wang, Haichuan, Tao, Junyan, Li, Xiaolei, Pes, Giovanni M., Mancarella, Serena, Giannelli, Gianluigi, Dombrowski, Frank, Evert, Matthias, Calvisi, Diego F., Chen, Xin, Evert, Katja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164528/
https://www.ncbi.nlm.nih.gov/pubmed/35655220
http://dx.doi.org/10.1186/s13046-022-02394-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164528/
https://www.ncbi.nlm.nih.gov/pubmed/35655220
http://dx.doi.org/10.1186/s13046-022-02394-2

Ejemplares similares